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Purpose: To investigate the role of baseline demographics, disease characteristics, and treatment responses
to ranibizumab during RIDE/RISE in predicting long-term treatment frequency with a criteria-based pro re nata
(PRN) regimen during the open-label extension (OLE).
Design: Pooled, retrospective, post hoc analysis from the phase III, randomized RIDE/RISE studies and
subsequent OLE.
Participants: Five hundred patients enrolled in the OLE after completion of the 36-month RIDE/RISE studies.
Methods: Summary statistics of RIDE/RISE baseline characteristics and treatment responses were gener-
ated by PRN ranibizumab 0.5 mg annualized injection frequency in the OLE (0 and >7 annualized injections).
Univariable regression and analysis of variance, and multivariable analysis of covariance were performed on the
annualized number of ranibizumab injections administered during the OLE versus baseline characteristics and
response to treatment during the RIDE/RISE studies.
Main Outcome Measures: Association of patient characteristics and responses to treatment during RIDE/
RISE with the observed ranibizumab treatment burden during the OLE.
Results: During the OLE, 121 patients required no treatment, 132 required >0 to 3 annualized injections, 159
required >3 to 7 annualized injections, and 88 required >7 annualized injections. Parameters identiﬁed in the
multivariable analysis as related to the annualized number of injections included the total number of rescue focal
macular lasers received during the core studies (P ¼ 0.0203), central foveal thickness at baseline (P ¼ 0.0002) and
month 36 (P< 0.0001), ﬂuorescein leakage area at month 36 (P¼ 0.0137), and glycated hemoglobin (HbA1c) levels at
month 36 (P¼ 0.0054). Patients receiving 0 versus>7 annualized injections during theOLE had, on average, a shorter
duration of diabetes and diabetic macular edema (DME) at baseline, were less likely to have proliferative diabetic
retinopathy at baseline, received fewer rescue focal macular laser treatments, and were more likely to experience
diabetic retinopathy severity scale improvement of 2 steps.
Conclusions: Patients who received less frequent injections during the RIDE/RISE OLE tended to have
less advanced disease at baseline and responded better to initial ranibizumab treatment, suggesting that
earlier antievascular endothelial growth factor treatment of center-involving DME with visual acuity loss may
decrease long-term treatment burden. Ophthalmology 2016;123:1716-1721 ª 2016 by the American Academy
of Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Diabetic macular edema (DME) is a leading cause of visual
impairment and blindness in working-age patients with
diabetic retinopathy (DR) in many developed countries.1
The ﬁrst validated treatment for DME, focal macular laser,
was established through the Early Treatment of Diabetic
Retinopathy Study (ETDRS) in the 1980s.2 More recently,
pharmacologic management has progressively replaced
focal macular laser as the primary treatment for center-
involved DME.3e6 Vascular endothelial growth factor
(VEGF)-A is a key cytokine in the development and pro-
gression of DME and DR,7,8 and its clinical blockade has
proven remarkably effective at improving visual acuity1716  2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc(VA) and reducing VA losses in populations with center-
involved DME with VA loss.3e6,9
On the basis of the results of the phase III RIDE/RISE
trials,6,10 ranibizumab (Lucentis, Genentech, Inc, South San
Francisco, CA) was the ﬁrst anti-VEGF pharmaceutical
agent approved by the US Food and Drug Administration
for the treatment of DME, becoming commercially avail-
able in 2012.11 During the RIDE/RISE studies, patients
receiving 0.3 mg or 0.5 mg monthly ranibizumab
injections rapidly experienced signiﬁcantly greater gains
in mean best-corrected visual acuity (BCVA) and de-
creases in retinal thickness compared with those receiving.
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patients who completed the RIDE/RISE 36-month trials
(n ¼ 582) were eligible to continue in the open-label
extension (OLE), of whom 500 (85.9%) elected to partici-
pate. There did not seem to be meaningful differences in the
baseline characteristics of patients who did or did not enroll
in the RIDE/RISE OLE.12
During the OLE, all patients were eligible to receive pro
re nata (PRN) 0.5 mg ranibizumab on the basis of predeﬁned
re-treatment criteria that assessed visual and anatomic sta-
bility. At each visit, treatment was administered if there was
evidence of DME on optical coherence tomography (OCT)
(evaluated by the investigator and deﬁned as the presence of
intraretinal ﬂuid or cysts, or subretinal ﬂuid due to DME and
not another cause; there were no absolute macular or central
subﬁeld thickness criteria that mandated treatment) or if
patients demonstrated a decrease in BCVA of 5 ETDRS
letters from the month 36 value (due to DME and not
another cause).12 Through a mean of 14.1 months of OLE
follow-up, overall the BCVA gains and anatomic OCT
thickness improvements achieved with monthly dosing
during RIDE/RISE were maintained. During the OLE the
mean annualized number of injections was 3.8, and there
was wide variability in the frequency of the required PRN
injections, with approximately one-quarter of patients
(24.2%) requiring no ranibizumab injections.
Given the societal impact of DME-associated vision loss,
coupled with the substantial burden to patients and the
health care system of delivering intravitreal anti-VEGF
treatments regularly,13 there is a need to identify and
better understand clinical markers that may be predictive
in assessing long-term treatment burdens for patients. The
objective of this analysis was to characterize those patients
who required less re-treatment during the OLE. Baseline
patient demographics, disease characteristics, and treatment
responses to ranibizumab during RIDE/RISE were studied
as potential predictors of long-term treatment burden.Methods
Study Design
Full methods of RIDE (NCT00473382) and RISE (NCT00473330)
have been described previously.6,10 Brieﬂy, patients with DME
(N ¼ 759) were randomized to receive monthly intravitreal ranibi-
zumab (0.3 or 0.5mg) or sham injections with rescue laser according
to prespeciﬁed criteria. At month 25, patients in the sham arm
crossed over to receive monthly ranibizumab (0.5 mg), and patients
originally assigned to ranibizumab continued to receive monthly
injections of their original dose through month 36. All patients
enrolled in the OLE (N¼ 500) were eligible to receive PRN 0.5 mg
ranibizumab according to predeﬁned re-treatment criteria. Treat-
ment was administered when DME was identiﬁed by the investi-
gator on OCT or when BCVA worsened by 5 ETDRS letters
versus month 36 (start of the OLE) as the result of DME. Patients
receiving ranibizumab treatment at any visit during the OLE were
subsequently observed every 30 (7) days. At the discretion of the
investigator, this could be extended to 60 (7) days or 90 (7) days
for patients who did not receive treatment. The difference between
arms in the distribution of time to ﬁrst injection during the OLE was
determined by using the log-rank test.Both trials were designed and conducted in accordance with the
principles of the Declaration of Helsinki and in compliance with
the Health Insurance Portability and Accountability Act. The study
protocols were approved by institutional review boards, ethics
committees, or as applicable. All patients provided written
informed consent before enrolling as study participants.
Variables Selected for Analysis
In this exploratory analysis, RIDE/RISE study baseline and treat-
ment response characteristics were summarized by the number of
criteria-based PRN injections received per follow-up year during
the OLE. The following baseline continuous or categoric variables
were examined: duration of diabetes, duration of DME, glycated
hemoglobin (HbA1c), BCVA, central foveal thickness (CFT), DR
severity, age, gender, race, blood pressure, kidney function, ﬂuo-
rescein angiography (FA) leakage, capillary loss, and focal/diffuse
edema. The following treatment response continuous or categoric
variables were examined at months 24 and 36 of the core studies:
BCVA, CFT, DR severity, HbA1c, FA leakage, capillary loss,
focal/diffuse edema, blood pressure, and kidney function. The
following continuous variables also were considered: the number
of laser treatments received by months 24 and 36, including rescue
focal macular laser and panretinal photocoagulation.
To illustrate the clinical relevance of the variables identiﬁed in
the univariable analysis, summary statistics for continuous vari-
ables (mean [standard deviation]) and categoric variables (n [%])
were examined by the number of annualized injections and pro-
vided for patients receiving the least frequent versus most frequent
treatment.
Univariable Regression/Analysis of Variance
A univariable regression analysis was performed on the number of
annualized injections received in the OLE versus RIDE/RISE
baseline and response to treatment characteristics for all patients
enrolled in the OLE. Patients were excluded from the analysis if
they were marked as “missing,” “cannot grade,” “not available,”
“not applicable,” or “questionable” for the corresponding variables.
Parameter estimates, their standard errors, and P values based on t
test for continuous variables and F-test for categoric variables were
reported.
Multivariable Analysis of Covariance
A multivariable analysis of covariance was performed on the
number of annualized injections in the OLE versus variables
selected from the univariable regression analysis that had overall
effect P values < 0.20, without the initial assigned treatment group
variable forced in, using stepwise selection (entry P value cutoff ¼
0.20, stay P value cutoff ¼ 0.05).
Results
The median time to ﬁrst injection in the OLE was 65 days, 59 days,
and 64 days for patients in the sham, ranibizumab 0.3 mg, and
ranibizumab 0.5 mg arms, respectively (log-rank P value ¼ 0.64).
The frequency distribution of the annualized number of criteria-
based PRN injections administered during the RIDE/RISE OLE is
provided in Figure 1. Patient demographics, baseline disease
characteristics, and responses to treatment variables from the
RIDE/RISE studies were correlated with the number of annualized
injections administered during the OLE. The continuous and
categoric variables that were signiﬁcant (at a ¼ 0.2 level) in the
univariable analysis are presented in Table 1. A multivariable
analysis was then performed using these variables. The parameters1717
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Figure 1. Frequency distribution of the annualized number of criteria-based pro re nata (PRN) injections administered during the RIDE/RISE open-label
extension (OLE).
Ophthalmology Volume 123, Number 8, August 2016that remained signiﬁcant at a ¼ 0.05 level in the multivariable
analysis are presented in Table 2. Less frequent injection during
the OLE was associated with thinner CFT at baseline and month
36, less FA leakage at month 36, and fewer rescue focal macular
laser treatments needed through month 36. HbA1c level at month
36 was inversely proportional to the number of annualized
injections during the OLE.
To further assess clinically relevant trends identiﬁed in the
univariable analysis, we compared the characteristics of patients
who required no injections (n ¼ 121; 24.2%) with those of patients
who received >7 annualized injections (n ¼ 88; 17.6%) during the
OLE (Table 3). Among patients who required the least frequent
treatment during the OLE (0 annualized injections) compared
with those who required the most (>7 annualized injections), the
mean duration of DME was shorter at baseline by approximately
9.6 months (25.2 vs. 34.8 months on average, respectively). The
proportion of patients with proliferative DR at baseline was
lower among those who required 0 annualized injections (27.3%)
than among patients requiring >7 annualized injections (47.7%).
Furthermore, the patients who required 0 annualized injections
during the OLE were more likely to experience a 2-step
improvement on the Diabetic Retinopathy Severity Scale at
months 24 and 36 (21.5% and 33.9%, respectively) compared with
patients requiring >7 annualized injections (12.5% and 17.0%,
respectively).Discussion
In the RIDE/RISE trials, patients with center-involved DME
causing VA loss to 20/40 or worse were treated monthly
with intravitreal ranibizumab for 36 (0.3 mg and 0.5 mg) or
12 (sham/crossover to 0.5 mg) months6,12 before enrolling
in the OLE, a PRN treatment regimen that continued for a
mean of 14.1 months.
The DRCR.network Protocol I trial also evaluated the
efﬁcacy of ranibizumab for center-involved DME causing
VA loss using monthly treatment followed by criteria-based
PRN re-treatment.4 In Protocol I, patients randomized to
ranibizumab (0.5 mg) received 4 monthly injections1718followed by visits every 4 weeks with PRN injections for
the ﬁrst year. By using this protocol through 1 year of
treatment, patients received a median of 8 to 9 injections.
During subsequent years of Protocol I, the median
numbers of ranibizumab injections decreased substantially
while earlier visual gains were maintained.14,15 This is
concordant with ﬁndings from the OLE that initial mean
visual gains achieved with monthly ranibizumab dosing can
be sustained with substantially fewer mean injections.12
The OLE was stopped when ranibizumab was approved by
theUSFood andDrugAdministration for treatment ofDME.12
During the OLE, the need for treatment varied greatly.
Approximately one-quarter (24.2%) of patients required no
additional ranibizumab injections to maintain the visual and
anatomic improvements achieved during RIDE/RISE.
Conversely, some patients continued to require frequent
treatment, with 17.6% receiving >7 annualized injections.
Markers of longer disease duration and more advanced
disease correlated with an increased frequency of long-term
treatment when comparing clinically relevant categories of
treatment burden during the OLE: patients receiving
0 versus patients receiving >7 annualized injections. Shorter
duration of both diabetes mellitus and DME correlated with
fewer PRN treatments in the OLE. Furthermore, the patients
requiring >7 annualized injections during the OLE were
more likely to have proliferative DR at baseline and less
likely to experience Diabetic Retinopathy Severity Scale
improvements of 2 steps. The current multivariable ana-
lyses similarly indicated reduced long-term treatment
burden during the OLE in patients with less retinal thick-
ening due to DME at baseline.
These data indicate that earlier anti-VEGF treatment of
DME causing VA loss may reduce the long-term treatment
burden. Correspondingly, earlier anti-VEGF treatment ap-
pears to result in better ultimate visual outcomes on a
population basis. During RIDE/RISE, delayed anti-VEGF
treatment resulted in less robust visual gains compared
with the outcomes achieved in patients initially randomized
Table 1. Candidate Variables Selected from Univariable Analyses
with P < 0.20
Parameter
Overall Effect
P Value
Continuous variables
Age, yrs 0.0654
Duration of diabetes at randomization, yrs 0.1206
Duration of diabetes at start of extension study, yrs 0.1207
Duration of DME at randomization, yrs 0.0312
Duration of DME at start of extension study, yrs 0.0312
Parent baseline BCVA, ETDRS letters (0e100) 0.0075
Parent BCVA at month 24, observed ETDRS letters 0.0010
Parent BCVA at month 36, observed ETDRS letters 0.0031
Parent baseline CFT (derived), mm <0.0001
Parent CFT (derived) at month 24, mm <0.0001
Parent CFT (derived) at month 36, mm <0.0001
DR severity score at baseline (1e10) 0.1633
Parent DR severity score at month 24 0.0113
Parent DR severity score at month 36 0.0018
Parent change from baseline DR severity score at
month 24
0.0119
Parent change from baseline DR severity score at
month 36
0.0018
Parent number of laser treatments by month 24 <0.0001
Parent number of laser treatments by month 36 <0.0001
Parent number of macular rescue laser treatments by
month 24
<0.0001
Parent number of macular rescue laser treatments by
month 36
<0.0001
Parent baseline HbA1c, % 0.1634
Parent HbA1c at month 24, % 0.0126
Parent HbA1c at month 36, % 0.0006
Parent change from baseline HbA1c at month 24, % 0.1741
Parent change from baseline HbA1c at month 36, % 0.0028
Parent baseline LOG HbA1c 0.1690
Parent LOG HbA1c at month 24 0.0136
Parent LOG HbA1c at month 36 0.0007
Parent change from baseline LOG HbA1c at
month 24
0.1843
Parent change from baseline LOG HbA1c at
month 36
0.0030
Parent baseline total area of ﬂuorescein leakage,
disc areas
0.0562
Parent total area of ﬂuorescein leakage at month
24, disc areas
<0.0001
Parent change from baseline leakage area at month
24, disc areas
0.0049
Parent total area of ﬂuorescein leakage at month
36, disc areas
<0.0001
Parent change from baseline leakage area at month
36, disc areas
0.0011
Parent diastolic blood pressure at month 36, mm Hg 0.1002
Parent change from baseline in diastolic blood
pressure at month 36, mm Hg
0.0909
Parent change from baseline in BUN at month
36, mg/dl
0.0956
Parent baseline glomerular ﬁltration rate,
ml/min/1.73 m2
0.1883
Parent glomerular ﬁltration rate at month
24, ml/min/1.73 m2
0.0878
Categoric Variables
Race 0.0678
Parent CFT 250 mm at month 24 <0.0001
Parent CFT 250 mm at month 36 <0.0001
Parent baseline DR severity scale categories
(60, 61 separate)
0.1372
(Continued)
Table 1. (Continued.)
Parameter
Overall Effect
P Value
Parent baseline DR severity category (60, 61
combined)
0.0962
Parent baseline DR severity score 53 (NPDR) vs.
>53 (PDR)
0.0078
Parent baseline DR severity score 60 vs. >60 0.1834
Parent change from baseline DRSS (2-step
improvement) (yes/no) at month 24
0.0437
Parent change from baseline DRSS (2-step
improvement) (yes/no) at month 36
0.0003
Presence of ﬂuorescein leakage (yes/no) at month 24 0.0034
Presence of ﬂuorescein leakage (yes/no) at month 36 <0.0001
BCVA ¼ best-corrected visual acuity; BUN ¼ blood urea nitrogen; CFT ¼
central foveal thickness; DME ¼ diabetic macular edema; DR ¼ diabetic
retinopathy; DRSS ¼ Diabetic Retinopathy Severity Scale; ETDRS ¼
Early Treatment Diabetic Retinopathy Study; HbA1c ¼ glycated hemo-
globin; LOG ¼ logarithm; NPDR ¼ nonproliferative diabetic retinopathy;
PDR ¼ proliferative diabetic retinopathy.
Wykoff et al  Ranibizumab for DME PRN Treatment Frequencyto ranibizumab. After 12 months of active treatment, pa-
tients initially randomized to sham treatment gained a mean
of 4.5 letters from baseline, compared with 10.6 and 11.1
mean letters with 0.3 mg and 0.5 mg ranibizumab, respec-
tively.3 Analogous ﬁndings have been reported from the
VISTA/VIVID phase III trials assessing aﬂibercept for the
treatment of DME.5
Furthermore, in the current series, improved anatomic
markers of DME, including less retinal thickening and less
FA leakage at the end of RIDE/RISE, correlated with fewer
treatments during the OLE. Of note, patients requiring more
injections during the OLE did so despite receiving more
focal macular laser treatments during RIDE/RISE, sug-
gesting that these patients may have had more chronic DME
with limited responsiveness to laser therapy. The role of
supplemental treatments in such patients with more recal-
citrant DME in the face of ongoing anti-VEGF therapy re-
quires further study.
In the current analysis, there was no clinically mean-
ingful correlation between HbA1c and annualized PRNTable 2. Multivariable Analysis of Covariance for Number of
Annualized Injections versus Independent Variable by Naïve
Stepwise Selection, without Core Study Treatment Forced In
Characteristics
Estimates
Coefﬁcient (SE) P Value
No. of rescue lasers by month 36 0.18 (0.08) 0.0203
CFT at baseline 0.004 (0.001) 0.0002
CFT at month 36 0.013 (0.002) <0.0001
Fluorescein leakage at month 36 0.11 (0.05) 0.0137
HbA1c at month 36 0.23 (0.08) 0.0054
CFT ¼ central foveal thickness; HbA1c ¼ glycated hemoglobin; SE ¼
standard error.
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Table 3. Selected Variables by Annualized Injections Received in
the Open-Label Extension
Annualized Number
of Injections
0 (n ¼ 121) >7 (n ¼ 88)
Duration of diabetes at baseline, yrs 16.0 (9.8) 18.0 (10.6)
Duration of DME at baseline, mean
(SD), yrs
2.1 (2.37) 2.9 (2.89)
Patients with PDR at baseline, % 27.3 47.7
Patients with 2-step improvement from baseline in DR severity, n (%)
Month 24 26 (21.5) 11 (12.5)
Month 36 41 (33.9) 15 (17.0)
No. of rescue lasers by month 36,
mean (SD)
0.9 (1.51) 2.3 (2.77)
CFT at baseline, mean (SD), mm 440.5 (150.27) 525.5 (160.78)
CFT at month 36, mean (SD), mm 145.9 (38.35) 271.7 (168.52)
FA leakage at month 36, mean (SD),
disc areas
1.3 (2.71) 4.1 (4.37)
HbA1c at month 36, mean (SD), % 8.2 (1.91) 7.5 (1.40)
CFT ¼ central foveal thickness; DME ¼ diabetic macular edema; DR ¼ dia-
betic retinopathy; FA ¼ ﬂuorescein angiography; HbA1c ¼ glycated hemo-
globin; PDR ¼ proliferative diabetic retinopathy; SD ¼ standard deviation.
Ophthalmology Volume 123, Number 8, August 2016injection frequency during the OLE. Multiple prospective
trials have conﬁrmed the value of improving long-term
blood glucose control toward minimizing the develop-
ment and progression of DR.16,17 Of note, patients with
HbA1c >12% were excluded from the RIDE/RISE trials,
thereby potentially limiting our ability to detect a mean-
ingful relationship between HbA1c and visual or anatomic
outcomes.Study Strengths and Limitations
Strengths of the current analysis include the randomized,
prospective design of the RIDE/RISE phase III trials and the
high retention rate of patients entering the OLE after
completion of the core studies, as well as the prespeciﬁed
anatomic and visual re-treatment criteria used in the OLE.
Limitations of the current study include its post hoc
exploratory approach and variable follow-up intervals of
patients within the OLE due to cessation of the study at a
given date unrelated to duration of patient participation in
the study.
The current data indicate that disease characteristics at
baseline and response to monthly ranibizumab treatment
may correlate with anti-VEGF treatment burden during
long-term DME management. Overall, patients who
received less frequent injections during the OLE tended to
have less advanced disease at baseline and responded better
to initial ranibizumab treatment, suggesting that earlier anti-
VEGF treatment of center-involving DME with VA loss
may decrease long-term treatment burden.
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